Tumor Lysis Syndrome Occurring After the Administration of Rituximab for Posttransplant Lymphoproliferative Disorder
Transplantation Proceedings2009Vol. 41(5), pp. 1946–1948
Citations Over TimeTop 17% of 2009 papers
Related Papers
- → Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era(2004)93 cited
- → Tumor Lysis Syndrome Occurring After the Administration of Rituximab for Posttransplant Lymphoproliferative Disorder(2009)13 cited
- → Effect of pre‐emptive rituximab on EBV DNA levels and prevention of post‐transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium(2024)6 cited
- → Treatment of Cutaneous Lymphoid Hyperplasia with the Monoclonal Anti-CD20 Antibody Rituximab(2011)26 cited
- → [Treatment of post-transplant lymphoproliferative disease with rituximab].(2014)